secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001628280-25-051035
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience Q3: Nimacimab + semaglutide shows 29% greater weight loss vs semaglutide alone; net loss $12.8M
--------------------------------------------------------------------------------

- Nimacimab plus semaglutide achieved 29% relative increase in weight loss vs semaglutide alone at 26 weeks; clean safety profile.
- Combination reduced waist circumference by 3.2 cm (1.25 inches) vs semaglutide alone.
- Rebound weight gain was 18.1% vs 49.8% for semaglutide alone over 12 weeks post-treatment.
- Q3 2025 net loss of $12.8M; cash $35.3M; runway into 2027.
- Extension study fully enrolled (43 patients); data expected Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000162828025051035/0001628280-25-051035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000162828025051035/skye-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-051035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer